CRISPR Therapeutics AG reported its financial results for the first quarter of 2025, revealing a total revenue of $865,504, a significant increase from $361,000 in the same period of 2024. The company did not generate any collaboration revenue during this quarter, consistent with the previous year. Operating expenses rose to $149.3 million, up from $141.1 million year-over-year, primarily driven by increased collaboration expenses related to its partnership with Vertex Pharmaceuticals. The net loss for the quarter was $136.0 million, compared to a net loss of $116.6 million in the first quarter of 2024, reflecting a worsening of $19.4 million.
The company's cash and cash equivalents decreased to $235.2 million as of March 31, 2025, down from $298.3 million at the end of 2024. Total current assets also fell to $1.87 billion, compared to $1.94 billion at the end of the previous fiscal year. The increase in current liabilities to $119.4 million from $87.8 million was largely attributed to a rise in accrued expenses, which jumped to $84.6 million from $41.1 million. The accumulated deficit increased to $1.50 billion, up from $1.37 billion at the end of 2024.
Strategically, CRISPR Therapeutics continues to advance its gene-editing technology, particularly through its collaboration with Vertex on the CASGEVY program, which has received regulatory approvals in multiple jurisdictions. The company is also exploring additional therapeutic areas, including type 1 diabetes and various cancers, through its innovative CRISPR/Cas9 platform. The company reported a total of 86.4 million common shares outstanding as of March 31, 2025, reflecting a slight increase from 85.7 million shares at the end of 2024.
Looking ahead, CRISPR Therapeutics anticipates continued investment in research and development, with expectations of incurring losses for the foreseeable future. The company has indicated that its existing cash, cash equivalents, and marketable securities will support its operations for at least the next 24 months. However, it acknowledges the need for additional financing to support long-term clinical development and commercialization efforts. The company plans to explore various funding options, including equity and debt financing, as well as potential collaborations to bolster its financial position.
About CRISPR Therapeutics AG
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.